{"id":3797,"date":"2024-12-23T22:28:28","date_gmt":"2024-12-23T21:28:28","guid":{"rendered":"https:\/\/www.celltrend.de\/?p=3797"},"modified":"2025-01-06T09:51:29","modified_gmt":"2025-01-06T08:51:29","slug":"study-about-autoantibodies-targeting-gpcr-in-pacvs","status":"publish","type":"post","link":"https:\/\/www.celltrend.de\/en\/study-about-autoantibodies-targeting-gpcr-in-pacvs\/","title":{"rendered":"Study about autoantibodies targeting GPCR in PACVS"},"content":{"rendered":"

A new study about autoantibodies targeting G-Protein-Coupled Receptors (GPCRs) in Post-Acute COVID Vaccination Syndrome (PACVS) was published. This study included 17 patients with symptoms compatible with PACVS after COVID-19 vaccination but they had not been infected with SARS-CoV-2. Serological tests showed that a high percentage of patients were positive for autoantibodies against GPCRs which are involved in the response to SARS-CoV-2. Some of the autoantibodies tested, were positively associated with symptoms like skin symptoms, chronic fatigue or hypertension. This analysis shows, that some levels of autoantibodies may serve as biomarkers for PACVS. Read the full article here<\/a>!<\/p>\n

 <\/p>\n

This table shows some characteristics of patients and their onset of symptoms.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

A new study about autoantibodies targeting G-Protein-Coupled Receptors (GPCRs) in Post-Acute COVID Vaccination Syndrome (PACVS) was published. This study included 17 patients with symptoms compatible with PACVS after COVID-19 vaccination but they had not been infected with SARS-CoV-2. Serological tests showed that a high percentage of patients were positive for autoantibodies against GPCRs which are…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"yst_prominent_words":[847,461,175,641,950,948,446,615,946,1074,482],"class_list":["post-3797","post","type-post","status-publish","format-standard","hentry","category-news-en","category-9","description-off"],"_links":{"self":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/posts\/3797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/comments?post=3797"}],"version-history":[{"count":4,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/posts\/3797\/revisions"}],"predecessor-version":[{"id":3812,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/posts\/3797\/revisions\/3812"}],"wp:attachment":[{"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/media?parent=3797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/categories?post=3797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/tags?post=3797"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/www.celltrend.de\/en\/wp-json\/wp\/v2\/yst_prominent_words?post=3797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}